About Artiva Biotherapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.artivabio.com/
Frequently Asked Questions
What is the 52-week range for ARTV?
The 52-week high is $14.53 and the 52-week low is $2.71.
What is the P/E ratio for ARTV?
The P/E ratio data is currently unavailable.
What is the dividend yield for ARTV?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -60.22%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.96.
Analyst Recommendation Trends
Wall Street analyst consensus for ARTV over the last few months:
Latest ARTV News
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-upPoster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile acros
Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren diseaseMean stimulated salivary flow increased from 0.4 to 1.1 mL/min among eight patients with baseline hyposalivation and available six-month dataUpdated safety data across 73 Phase 2a basket study patients support the potential for outpatient administration,
Artiva Biotherapeutics Presents Updated Clinical, Safety And Translational Data For AlloNK In Combination With Rituximab At 17th ISSjD 2026 In Paris
Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding,
Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-upSAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT. To access the audio webcast and subsequent archived reco
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2a basket trial, each with at least six months of follow-up, including at least 10 patients who would meet key eligibility criteria for the Phase 3 registrational trial in refractory RA Updated clinical data expected in the second half of 2026 from at least 10 patients with Sjögren disease (SjD) and
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Aslan Fred | +315,000 | - | - |
| 2026-09-15 | Aslan Fred | +110,000 | - | - |
| 2026-09-10 | Aslan Fred | +155,000 | - | - |
| 2026-09-10 | Aslan Fred | +45,000 | - | - |
| 2026-09-10 | Stoppel Laura | +16,250 | - | - |
| 2026-09-10 | Sorg Elaine K. | +16,250 | - | - |
| 2026-09-10 | Baker Daniel G. | +16,250 | - | - |
| 2026-09-10 | MOORE ALISON | +16,250 | - | - |
| 2026-09-10 | DANIELS BRIAN | +16,250 | - | - |
| 2026-09-10 | RA CAPITAL MANAGEMENT, L.P. | +16,250 | - | - |
| 2026-09-10 | HOUGEN ELIZABETH L | +16,250 | - | - |
| 2026-09-09 | Banerjee Subhashis | +85,000 | - | - |
| 2026-09-09 | Banerjee Subhashis | +30,000 | - | - |
| 2026-09-09 | Miralles Gines Diego | +135,000 | - | - |
| 2026-09-09 | Miralles Gines Diego | +45,000 | - | - |
| 2026-09-09 | Horan Christopher | +120,000 | - | - |
| 2026-09-09 | Horan Christopher | +40,000 | - | - |
| 2026-09-09 | Bush Jennifer | +135,000 | - | - |
| 2026-09-09 | Bush Jennifer | +45,000 | - | - |
| 2026-09-08 | Aslan Fred | -23,429 | $10.9158 | $255,746 |
| 2026-09-08 | Stoppel Laura | +13,750 | - | - |
| 2026-09-08 | Sorg Elaine K. | +13,750 | - | - |
| 2026-09-08 | Baker Daniel G. | +13,750 | - | - |
| 2026-09-08 | MOORE ALISON | +13,750 | - | - |
| 2026-09-08 | DANIELS BRIAN | +13,750 | - | - |
| 2026-09-08 | RA CAPITAL MANAGEMENT, L.P. | +13,750 | - | - |
| 2026-09-08 | HOUGEN ELIZABETH L | +13,750 | - | - |
| 2026-09-03 | Banerjee Subhashis | -1,100 | $11.1556 | $12,271 |
| 2026-09-03 | Aslan Fred | -61,888 | $11.1555 | $690,392 |
| 2026-09-03 | Horan Christopher | -10,366 | $11.1555 | $115,638 |
| 2026-09-03 | Bush Jennifer | -8,391 | $11.1555 | $93,606 |
| 2026-08-27 | Banerjee Subhashis | -5,306 | - | - |
| 2026-08-27 | Banerjee Subhashis | -8,222 | $12.0087 | $98,736 |
| 2026-08-27 | Banerjee Subhashis | +5,306 | $1.92 | $10,188 |
| 2026-08-18 | Banerjee Subhashis | -429 | - | - |
| 2026-08-18 | Banerjee Subhashis | -429 | $12 | $5,148 |
| 2026-08-18 | Banerjee Subhashis | +429 | $1.92 | $824 |
| 2026-07-31 | RA CAPITAL MANAGEMENT, L.P. | +24,944 | $9.93 | $247,694 |
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. | +20,824 | $9.99 | $208,032 |
| 2026-07-24 | RA CAPITAL MANAGEMENT, L.P. | +41,319 | $9.99 | $412,777 |
| 2026-07-23 | RA CAPITAL MANAGEMENT, L.P. | +59,880 | $9.96 | $596,405 |
| 2026-07-22 | RA CAPITAL MANAGEMENT, L.P. | +84,124 | $9.93 | $835,351 |
| 2026-07-21 | RA CAPITAL MANAGEMENT, L.P. | +120,582 | $9.55 | $1,151,558 |
| 2026-07-17 | RA CAPITAL MANAGEMENT, L.P. | +7,882 | $8.95 | $70,544 |
| 2026-07-16 | RA CAPITAL MANAGEMENT, L.P. | +152,472 | $8.93 | $1,361,575 |
| 2026-07-13 | RA CAPITAL MANAGEMENT, L.P. | +6,522 | $8.94 | $58,307 |
| 2026-07-13 | RA CAPITAL MANAGEMENT, L.P. | +6,552 | $8.94 | $58,575 |
| 2026-07-10 | RA CAPITAL MANAGEMENT, L.P. | +15,102 | $8.97 | $135,465 |
| 2026-06-16 | RA Capital Healthcare Fund LP | +124,893 | $8.89 | $1,110,299 |
| 2026-06-15 | RA Capital Healthcare Fund LP | +15,414 | $8.99 | $138,572 |
| 2026-06-12 | RA Capital Healthcare Fund LP | +391,019 | $8.57 | $3,351,033 |
| 2026-06-11 | RA Capital Healthcare Fund LP | +548,580 | $7.91 | $4,339,268 |
| 2026-06-10 | RA Capital Healthcare Fund LP | +103 | $7 | $721 |
| 2026-06-09 | RA Capital Healthcare Fund LP | +479,039 | $6.91 | $3,310,159 |
| 2026-05-19 | Raymon Heather | -3,095 | $9.0078 | $27,879 |
| 2026-05-19 | Banerjee Subhashis | -7,037 | $9.0076 | $63,386 |
| 2026-05-19 | Aslan Fred | -27,116 | $9.0077 | $244,253 |
| 2026-05-19 | Horan Christopher | -7,002 | $9.0078 | $63,073 |
| 2026-05-19 | Bush Jennifer | -8,790 | $9.0078 | $79,179 |
| 2026-05-18 | Miralles Gines Diego | +232,500 | - | - |
| 2026-05-18 | Miralles Gines Diego | +77,500 | - | - |
| 2026-05-11 | GC Corp. | +347,222 | $11.52 | $3,999,997 |
| 2026-05-11 | GC Corp. | +1,085,069 | $11.52 | $12,499,995 |
| 2026-05-11 | RA Capital Healthcare Fund LP | +2,170,138 | $11.5199 | $24,999,773 |
| 2026-05-11 | RA Capital Healthcare Fund LP | +6,510,416 | $11.52 | $74,999,992 |
| 2026-03-10 | Huston Thad Allen | +220,000 | - | - |
| 2026-02-18 | Sorg Elaine K. | +27,500 | - | - |
| 2026-02-15 | Raymon Heather | -1,521 | $4 | $6,084 |
| 2026-02-15 | Raymon Heather | +46,000 | - | - |
| 2026-02-15 | Banerjee Subhashis | +102,000 | - | - |
| 2026-02-15 | Aslan Fred | -14,600 | $4 | $58,400 |
| 2026-02-15 | Aslan Fred | +366,850 | - | - |
| 2026-02-15 | Horan Christopher | -2,187 | $4 | $8,748 |
| 2026-02-15 | Horan Christopher | +117,300 | - | - |
| 2026-02-15 | Bush Jennifer | -3,515 | $4 | $14,060 |
| 2026-02-15 | Bush Jennifer | +117,300 | - | - |
| 2025-12-15 | Aslan Fred | -3,187 | $6 | $19,122 |
| 2025-12-12 | Raymon Heather | -10,259 | - | - |
| 2025-12-12 | Raymon Heather | -11,399 | - | - |
| 2025-12-12 | Raymon Heather | -14,819 | - | - |
| 2025-12-12 | Raymon Heather | -12,539 | - | - |
| 2025-12-12 | Raymon Heather | -18,239 | - | - |
| 2025-12-12 | Raymon Heather | +67,253 | - | - |
| 2025-12-12 | Aslan Fred | -319,331 | - | - |
| 2025-12-12 | Aslan Fred | -113,999 | - | - |
| 2025-12-12 | Aslan Fred | -26,450 | - | - |
| 2025-12-12 | Aslan Fred | -257,319 | - | - |
| 2025-12-12 | Aslan Fred | -51,463 | - | - |
| 2025-12-12 | Aslan Fred | -100,577 | - | - |
| 2025-12-12 | Aslan Fred | +869,136 | - | - |
| 2025-12-12 | Horan Christopher | -20,519 | - | - |
| 2025-12-12 | Horan Christopher | -9,119 | - | - |
| 2025-12-12 | Horan Christopher | -77,519 | - | - |
| 2025-12-12 | Horan Christopher | +107,156 | - | - |
| 2025-12-12 | Bush Jennifer | -20,519 | - | - |
| 2025-12-12 | Bush Jennifer | -14,202 | - | - |
| 2025-12-12 | Bush Jennifer | -9,119 | - | - |
| 2025-12-12 | Bush Jennifer | -41,039 | - | - |
| 2025-12-12 | Bush Jennifer | +84,877 | - | - |
| 2025-11-17 | Aslan Fred | -6,375 | $3.376 | $21,522 |
| 2025-11-15 | Raymon Heather | -1,375 | $3.25 | $4,469 |
| 2025-11-15 | Krishnamohan Neha | -3,490 | $3.25 | $11,343 |
| 2025-11-15 | Aslan Fred | -6,347 | $3.25 | $20,628 |
| 2025-11-15 | Horan Christopher | -1,899 | $3.25 | $6,172 |
| 2025-11-15 | Bush Jennifer | -3,055 | $3.25 | $9,929 |
| 2025-10-17 | Aslan Fred | -25,500 | $6 | $153,000 |